SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Feb 2022 Evaluate
The sales slipped to Rs. 384.80 millions, down -44.25% for the December 2021 quarter as against Rs. 690.20 millions during the year-ago period.The Net Loss for the quarter ended December 2021 is Rs. -224.30 millions as compared to Net Profit of Rs. 19.00 millions of corresponding quarter ended December 2020Operating profit Margin for the quarter ended December 2021 slipped to -140.60% as compared to 104.40% of corresponding quarter ended December 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 384.80 690.20 -44.25 1940.00 2637.00 -26.43 3435.60 1580.90 117.32
Other Income 23.80 71.70 -66.81 100.00 129.90 -23.02 207.40 308.70 -32.82
PBIDT -140.60 104.40 -234.67 -433.00 296.00 -246.28 212.40 -313.50 -167.75
Interest 19.10 18.90 1.06 56.00 56.60 -1.06 75.20 52.70 42.69
PBDT -159.70 85.50 -286.78 -489.00 239.40 -304.26 137.20 -520.20 -126.37
Depreciation 64.60 66.40 -2.71 193.70 200.00 -3.15 265.70 269.10 -1.26
PBT -224.30 19.10 -1274.35 -682.70 39.40 -1832.74 -128.50 -789.30 -83.72
TAX 0.00 0.10 0.00 0.00 0.40 0.00 15.60 171.00 -90.88
Deferred Tax 0.00 0.10 0.00 0.00 0.40 0.00 -7.10 -227.80 -96.88
PAT -224.30 19.00 -1280.53 -682.70 39.00 -1850.51 -144.10 -960.30 -84.99
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) -36.54 15.13 -341.56 -22.32 11.22 -298.84 6.18 -19.83 -131.18

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×